CA2536280A1 - A pharmaceutical composition for the prevention and treatment of addiction in a mammal - Google Patents

A pharmaceutical composition for the prevention and treatment of addiction in a mammal Download PDF

Info

Publication number
CA2536280A1
CA2536280A1 CA002536280A CA2536280A CA2536280A1 CA 2536280 A1 CA2536280 A1 CA 2536280A1 CA 002536280 A CA002536280 A CA 002536280A CA 2536280 A CA2536280 A CA 2536280A CA 2536280 A1 CA2536280 A1 CA 2536280A1
Authority
CA
Canada
Prior art keywords
chlorophenyl
phenyl
aza
hydroxy
bicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002536280A
Other languages
English (en)
French (fr)
Inventor
Jotham Wadsworth Coe
Philip Andrew Iredale
Stanton Furst Mchardy
Stafford Mclean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2536280A1 publication Critical patent/CA2536280A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002536280A 2003-08-21 2004-08-09 A pharmaceutical composition for the prevention and treatment of addiction in a mammal Abandoned CA2536280A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49680303P 2003-08-21 2003-08-21
US60/496,803 2003-08-21
PCT/IB2004/002596 WO2005018645A1 (en) 2003-08-21 2004-08-09 A pharmaceutical composition for the prevention and treatment of addiction in a mammal

Publications (1)

Publication Number Publication Date
CA2536280A1 true CA2536280A1 (en) 2005-03-03

Family

ID=34216038

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002536280A Abandoned CA2536280A1 (en) 2003-08-21 2004-08-09 A pharmaceutical composition for the prevention and treatment of addiction in a mammal

Country Status (7)

Country Link
US (1) US20050043327A1 (https=)
EP (1) EP1658082A1 (https=)
JP (1) JP2007502808A (https=)
BR (1) BRPI0413693A (https=)
CA (1) CA2536280A1 (https=)
MX (1) MXPA06002035A (https=)
WO (1) WO2005018645A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1440059B1 (en) * 2001-10-22 2008-04-16 Pfizer Products Inc. 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
US7132426B2 (en) * 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AU2006305104B2 (en) * 2005-10-21 2009-10-22 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
JP5269795B2 (ja) * 2006-09-29 2013-08-21 グリーン・クロス・コーポレイション カンナビノイドｃｂ１受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
JP3145620U (ja) 2008-07-30 2008-10-16 公二 平井 擬似嗜好物品
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
US9663463B2 (en) 2013-11-20 2017-05-30 Sanwa Kagaku Kenkyusho Co., Ltd. 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
KR20180004734A (ko) 2015-05-20 2018-01-12 가부시키가이샤산와카가쿠켄큐쇼 신규 3-아자비시클로［3.1.0］헥산 유도체의 염의 결정 및 그의 의약 용도
CA3036382A1 (en) * 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
CN110352055A (zh) * 2017-03-02 2019-10-18 株式会社三和化学研究所 酒精使用障碍的治疗药物
SG11202007422QA (en) * 2018-02-05 2020-09-29 Alkermes Inc Compounds for the treatment of pain
WO2023064228A1 (en) * 2021-10-11 2023-04-20 Anebulo Pharmaceuticals, Inc. Method of treating addiction
AU2022362107A1 (en) 2021-10-11 2024-05-02 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1440059B1 (en) * 2001-10-22 2008-04-16 Pfizer Products Inc. 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
BRPI0413693A (pt) 2006-10-24
WO2005018645A1 (en) 2005-03-03
EP1658082A1 (en) 2006-05-24
JP2007502808A (ja) 2007-02-15
US20050043327A1 (en) 2005-02-24
MXPA06002035A (es) 2006-05-17

Similar Documents

Publication Publication Date Title
US20050043327A1 (en) Pharmaceutical composition for the prevention and treatment of addiction in a mammal
AU2003304527B2 (en) Uses of adenosine A2a receptor antagonists
JP6604664B2 (ja) 核内受容体に対して活性な化合物
Kotzer et al. The antitussive activity of δ-opioid receptor stimulation in guinea pigs
Mosberg et al. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands
Megens et al. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs
TW201000481A (en) Novel phenylimidazole derivatives as PDE10A enzyme inhibitors
Cappendijk et al. The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine
JP2003515602A (ja) 免疫抑制薬として有用な２，４−ジアミノピリミジン化合物
AU2014312261A1 (en) Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases
JP4778894B2 (ja) 不安障害の治療方法
Mennini et al. Mechanism of action of anxiolytic drugs
Tamaoki et al. Pharmacological properties of 3-amino-5, 6, 7, 8-tetrahydro-2-{4-[4-(quinolin-2-yl) piperazin-1-yl] butyl} quinazolin-4 (3 H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model
JPH0717862A (ja) 脂肪組織の成長のインヒビターとしてのアンギオテンシン（ａｉｉ）拮抗物質
CA2772922C (en) Thiazoles derivatives for treating or preventing anxiety disorders
V Ivachtchenko et al. Small molecule 5-HT6R ligands: A comprehensive insight into their selectivity and activity
US20040224963A1 (en) Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20060106040A1 (en) Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20040224962A1 (en) Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
CN115611856B (zh) 一种哌啶衍生物及其药物组合物、制备方法和用途
MXPA04012389A (es) Composiciones anti-inflamatorias y metodos de uso.
CN101325974A (zh) 用于治疗锥体外综合征和其它运动障碍的腺苷a2a受体拮抗剂
Mostallino et al. The novel synthesized naltrexone-related MOR antagonist AT-99 counteracts dopamine releasing and behavioral depressant morphine-induced effects
CA2533177A1 (en) Treatment of male sexual dysfunction
JP2005534665A (ja) うつ病の治療のためのｐｄｅ−ｖ阻害物質及びｎｋ１拮抗薬の組合せ

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued